후천성 안검 하수 : 시장 인사이트, 역학 및 시장 예측(2036년)

Acquired Blepharoptosis Insights and Trends

• The acquired blepharoptosis market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2026-2036). This growth in market revenue is primarily propelled by an expanding geriatric populations, growing awareness of functional and cosmetic ophthalmic conditions, and the emergence of non-surgical pharmacologic therapies.
• Increasing cases of acquired blepharoptosis are strongly associated with aging-related degeneration of the levator aponeurosis, neurological disorders, trauma, contact lens use, and post-surgical complications. Epidemiological studies indicate acquired ptosis is the predominant form of blepharoptosis, particularly among individuals older than 40 years.
• Surgical correction procedures, including levator advancement and frontalis sling surgery, continue to represent the standard of care for moderate-to-severe ptosis; however, increasing patient preference for minimally invasive and office-based therapies is expected to support expansion of the pharmacologic treatment segment.
• Oxymetazoline hydrochloride (UPNEEQ) represents the first FDA-approved non-surgical therapy for acquired blepharoptosis. There are no other FDA-approved pharmacologic treatments for acquired blepharoptosis currently available. Surgery (blepharoplasty/levator repair) remains the standard definitive treatment for many cases.
• Despite recent therapeutic advances, a major unmet need remains for long-acting therapies capable of providing durable eyelid elevation with improved tolerability and effectiveness across broader patient populations, including neurogenic and severe ptosis subtypes. Current pharmacologic therapies require continuous administration and lack long-term efficacy data beyond short treatment durations.

DelveInsight's "Acquired Blepharoptosis- Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of acquired blepharoptosis, historical and forecasted epidemiology, as well as the acquired blepharoptosis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The acquired blepharoptosis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, acquired blepharoptosis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across the 7MM regions. The report highlights key unmet medical needs in acquired blepharoptosis and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, and Spain and the United Kingdom

Asia-Pacific: Japan

Acquired Blepharoptosis Understanding and Treatment Algorithm

Acquired Blepharoptosis Overview and Diagnosis

Acquired Blepharoptosis is a condition characterized by abnormal drooping of the upper eyelid that develops later in life rather than being present at birth. It is one of the most common eyelid disorders seen in ophthalmology and may occur unilaterally or bilaterally. The condition can impair superior visual fields, reduce quality of life, and create cosmetic concerns. The most common form is aponeurotic ptosis, typically related to aging and dehiscence of the levator aponeurosis, although neurogenic, myogenic, mechanical, and traumatic causes are also recognized. Risk factors include aging, long-term contact lens use, ocular surgery (especially cataract surgery), and neurologic disease.

Diagnosis of Acquired Blepharoptosis relies on a detailed ophthalmic and neurologic evaluation. Clinical assessment includes measuring margin reflex distance (MRD1), palpebral fissure height, levator muscle function, and eyelid crease position. Physicians also evaluate for associated symptoms such as diplopia, fatigue, anisocoria, or ocular motility abnormalities to exclude serious neurologic causes like Horner syndrome, third cranial nerve palsy, or myasthenia gravis. Differential diagnosis is essential because ptosis may occasionally indicate systemic or orbital disease. Imaging or laboratory investigations are performed when secondary neurologic or structural causes are suspected.

Current Acquired Blepharoptosis Treatment Landscape

Pharmacological Treatment: Pharmacological management of acquired blepharoptosis has expanded with the introduction of topical Oxymetazoline hydrochloride (UPNEEQ), currently the primary approved non-surgical therapy for acquired ptosis. Oxymetazoline is an a-adrenergic agonist that stimulates Muller's muscle, producing temporary elevation of the upper eyelid and improvement in superior visual fields. It is mainly indicated for patients with mild-to-moderate ptosis or for those who are not ideal surgical candidates. Clinical studies have demonstrated rapid onset of action and measurable improvements in eyelid height, although the treatment remains symptomatic and requires continued use for sustained benefit.

Surgical Treatment: Surgical correction remains the gold standard for moderate-to-severe acquired blepharoptosis and is selected based on the severity of ptosis and levator muscle function. The most common procedure, levator advancement or aponeurosis repair, is widely used in aponeurotic ptosis associated with aging and involves tightening or reattaching the levator aponeurosis. Muller muscle-conjunctival resection (MMCR) is preferred for patients with good levator function and favorable pharmacologic testing, while frontalis suspension surgery is used when levator function is poor by linking the eyelid to the frontalis muscle. Surgical management aims to restore eyelid symmetry, improve visual obstruction, and enhance cosmetic appearance, with generally high functional and patient satisfaction outcomes.

Acquired Blepharoptosis Epidemiology

The epidemiology section of the acquired blepharoptosis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of acquired blepharoptosis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings from Acquired Blepharoptosis Epidemiological Analysis and Forecast

• According to the secondary search, acquired blepharoptosis is the predominant form of ptosis seen in adults. General adult prevalence ranges from 4.7%-13.5%, with prevalence increasing substantially with age.
• In the UK, acquired blepharoptosis affects about 11.5% of adults aged 50 years and older. The condition becomes more common with increasing age, rising from around 2.4% in people aged 50-59 years to approximately 20.8% in those aged 70 years and above, showing a clear age-related increase in prevalence.

Acquired Blepharoptosis Market Outlook

The acquired blepharoptosis therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2026-2036).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the acquired blepharoptosis market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Acquired Blepharoptosis Drug Analysis & Competitive Landscape

The acquired blepharoptosis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the acquired blepharoptosis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the acquired blepharoptosis therapeutics market.

Approved Therapies for Acquired Blepharoptosis

Oxymetazoline hydrochloride (UPNEEQ): RVL Pharmaceuticals

Oxymetazoline hydrochloride ophthalmic solution 0.1% (UPNEEQ) is a prescription alpha-adrenergic agonist indicated for the treatment of acquired blepharoptosis. It acts primarily as an a1-adrenergic receptor agonist (with some a2 activity), stimulating Muller's muscle in the upper eyelid to produce a measurable elevation of the lid margin after topical ocular administration. Following once-daily instillation of one drop in each affected eye, pharmacodynamic effects begin within minutes and typically last several hours. In December 2025, Santen Pharmaceutical reported that it has obtained manufacturing and marketing approval in Japan for oxymetazoline hydrochloride (UPNEEQ) Mini Ophthalmic Solution 0.1% for treatment for acquired blepharoptosis.

• In July 2020, RVL Pharmaceuticals reported that the U.S. Food and Drug Administration (FDA) has approved oxymetazoline hydrochloride ophthalmic solution 0.1% (UPNEEQ) for acquired blepharoptosis, or ptosis.
• In April 2026, Santen Pharmaceutical reported that it will launch oxymetazoline hydrochloride (UPNEEQ) Mini Ophthalmic Solution 0.1%, for acquired blepharoptosis, in Japan on May 15, 2026.

Acquired Blepharoptosis Pipeline Analysis

LEV102: Levation Pharma

LEV-102 is a proprietary, odorless, colorless, rapidly drying aqueous gel applied in small amounts to the upper eyelid, similar to eyeshadow and potentially used as an eyeshadow primer. Its active ingredient is oxymetazoline, a drug approved in the U.S. for over 40 years. The formulation includes stabilizers and permeation enhancers that allow the drug to penetrate the upper eyelid and act on Muller's muscle, an involuntary muscle that helps elevate the upper eyelid. By stimulating mild contraction of this muscle, LEV-102 is intended to raise the upper eyelid, improving upper visual field and cosmetic appearance. It does not target voluntary eyelid muscles and is designed for once-daily topical application.

Acquired Blepharoptosis Market Segmentation

DelveInsight's 'Acquired Blepharoptosis - Market Insights, Epidemiology, and Market Forecast - 2036' report provides a detailed outlook of the current and future acquired blepharoptosis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Acquired Blepharoptosis Market Size by Countries

The acquired blepharoptosis market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the US held a significant share of the overall 7MM (Seven Major Markets) acquired blepharoptosis market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Acquired Blepharoptosis Market Size by Therapies

Acquired blepharoptosis market size by therapies is categorized into current and emerging markets for the study period 2022-2036.

Acquired Blepharoptosis Drug Uptake

This section focuses on the sales uptake of potential of acquired blepharoptosis drugs that have recently been launched or are anticipated to be launched in the acquired blepharoptosis market between 2022 and 2036. It estimates the market penetration of acquired blepharoptosis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the acquired blepharoptosis market.

The emerging acquired blepharoptosis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the acquired blepharoptosis market.

Acquired Blepharoptosis Market Access and Reimbursement

DelveInsight's 'Acquired Blepharoptosis- Market Insights, Epidemiology, and Market Forecast - 2036' report provides a descriptive overview of the market access and reimbursement scenario of acquired blepharoptosis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current acquired blepharoptosis market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the acquired blepharoptosis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or acquired blepharoptosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the acquired blepharoptosis unmet needs.

Acquired Blepharoptosis: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Miami, Massachusetts Eye and Ear, Johns Hopkins University, Moorfields Eye Hospital among others.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the acquired blepharoptosis market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Acquired Blepharoptosis Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase I/II and III stages and examines companies involved in developing targeted therapeutics for acquired blepharoptosis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging acquired blepharoptosis therapies.

Acquired Blepharoptosis Report Insights

• Acquired Blepharoptosis Patient Population
• Therapeutic Approaches
• Acquired Blepharoptosis Pipeline Analysis
• Acquired Blepharoptosis Market Size and Trends
• Acquired Blepharoptosis Market Opportunities
• Impact of Upcoming Therapies

Acquired Blepharoptosis Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Acquired Blepharoptosis Epidemiology Segmentation
• Competitive Landscape
• Highly Analyzed Acquired Blepharoptosis Market
• Acquired Blepharoptosis Drugs Uptake

Acquired Blepharoptosis Report Assessment

• Acquired Blepharoptosis Current Treatment Practices
• Unmet Needs
• Acquired Blepharoptosis Pipeline Product Profiles
• Acquired Blepharoptosis Market Attractiveness

Key Questions:

• How common is acquired blepharoptosis?
• What are the key findings of acquired blepharoptosis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022-2036)?
• What are the currently available treatments for acquired blepharoptosis?
• What are the disease risk, burden, and unmet needs of acquired blepharoptosis?
• At what CAGR is the acquired blepharoptosis market and its epidemiology is expected to grow in the 7MM during the forecast period (2026-2036)?
• How would the unmet needs impact the acquired blepharoptosis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of acquired blepharoptosis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2026-2036)?
• How many companies are currently developing therapies for the treatment of acquired blepharoptosis?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the acquired blepharoptosis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for acquired blepharoptosis?

The primary treatment goal is to restore normal eyelid position so that the visual axis is no longer obstructed, thereby improving the patient's visual field and overall functional ability. In addition to functional correction, achieving eyelid symmetry is important to maintain natural ocular appearance. Patient satisfaction is also a key consideration, particularly in cases where cosmetic concerns significantly impact quality of life.

2. What are the challenges in managing acquired blepharoptosis?

Management is challenging due to the need for accurate identification of the underlying cause, which may be aponeurotic, neurogenic, myogenic, mechanical, or traumatic in origin. The variability in severity and presentation among patients makes standardized treatment difficult, often requiring individualized surgical planning. There is also a risk of suboptimal outcomes such as undercorrection, overcorrection, or postoperative asymmetry, which may necessitate revision procedures.

3. What are the key factors driving the growth of the acquired blepharoptosis market?

The market is primarily driven by the increasing aging population, as involutional changes in the eyelid are more common in older adults. Improved awareness of eyelid disorders and better access to ophthalmic care are leading to higher diagnosis and treatment rates.

4. How will the acquired blepharoptosis Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current acquired blepharoptosis landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

3.1.. Market Share (%) Distribution of Acquired Blepharoptosis by Therapies in 2025

3.2.. Market Share (%) Distribution of Acquired Blepharoptosis by Therapies in 2036

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

7.1.. Introduction

• 7.2. Types

7.3.. Causes

7.4.. Pathophysiology

7.5.. Symptoms

7.6.. Risk Factor

7.7.. Diagnosis

7.7.1.. Diagnostic Algorithm

7.7.2.. Diagnostic Guidelines

7.8.. Treatment and Management

7.8.1.. Treatment Algorithm

7.8.2.. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
• 8.3. Total Prevalent Cases of Acquired Blepharoptosis in the 7MM
• 8.4. Total Diagnosed Prevalent Cases of Acquired Blepharoptosis in the 7MM
• 8.5. The US
  • 8.5.1. Total Prevalent Cases of Acquired Blepharoptosis
  • 8.5.2. Total Diagnosed Prevalent Cases of Acquired Blepharoptosis
  • 8.5.3. Age-Specific Cases of Acquired Blepharoptosis
  • 8.5.4. Gender-specific Cases of Acquired Blepharoptosis
  • 8.5.5. Treated Cases of Acquired Blepharoptosis
• 8.6. EU4 and the UK
  • 8.6.1. Total Prevalent Cases of Acquired Blepharoptosis
  • 8.6.2. Total Diagnosed Prevalent Cases of Acquired Blepharoptosis
  • 8.6.3. Age-Specific Cases of Acquired Blepharoptosis
  • 8.6.4. Gender-specific Cases of Acquired Blepharoptosis
  • 8.6.5. Treated Cases of Acquired Blepharoptosis
• 8.7. Japan
  • 8.7.1. Total Prevalent Cases of Acquired Blepharoptosis
  • 8.7.2. Total Diagnosed Prevalent Cases of Acquired Blepharoptosis
  • 8.7.3. Age-Specific Cases of Acquired Blepharoptosis
  • 8.7.4. Gender-specific Cases of Acquired Blepharoptosis
  • 8.7.5. Treated Cases of Acquired Blepharoptosis

9. Patient Journey

10. Marketed Therapies

• 10.1. Competitive Landscape: Marketed Drugs
• 10.2. Oxymetazoline hydrochloride (UPNEEQ): RVL Pharmaceuticals
  • 10.2.1. Drug Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy

11. Pipeline Therapies: Emerging Drugs

• 11.1. Competitive Landscape: Emerging Drugs
• 11.2. LEV102: Levation Pharma
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views

12. Acquired Blepharoptosis: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of Acquired Blepharoptosis in the 7MM
• 12.6. Market Size of Acquired Blepharoptosis by Therapies in the 7MM
• 12.7. The US Market Size
  • 12.7.1. Total Market Size of Acquired Blepharoptosis
  • 12.7.2. Market Size of Acquired Blepharoptosis by Therapies
• 12.8. Market Size of Acquired Blepharoptosis in the EU4 and the UK
  • 12.8.1. Total Market Size of Acquired Blepharoptosis
  • 12.8.2. Market Size of Acquired Blepharoptosis by Therapies

12.9.. Japan Market Size

• 12.9.1. Total Market Size of Acquired Blepharoptosis
• 12.9.2. Market Size of Acquired Blepharoptosis by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Acquired Blepharoptosis Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight